Tag: Eversense
Ascensia extends PASS program
March 14, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings will extend the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversense E3 CGM System more affordably, the program offers major savings for eligible individuals looking to experience the unique benefits of the only long-term CGM system available. Eligible individuals will pay only $99 out of pocket for an unlimited number of six-month Eversense E3 systems under...
Ascensia announces coverage expansion for CGM system
February 12, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings have announced that Medicare has significantly expanded access to the Eversense E3 CGM System with the implementation of local coverage determinations that provide access to implantable CGM for basal-only patients. Medicare coverage has been expanded for implantable CGMs to include all people with diabetes using insulin, removing the previous requirement for multiple inulin administrations per day. Coverage has also been updated...
Ascensia: ‘This is Diabetes, This is Real’
September 19, 2023HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care, owner of the CONTOUR blood glucose monitoring system portfolio and exclusive distributor of the Eversense continuous glucose monitoring system, has opened submissions for its art and photo competition in support of World Diabetes Day 2023. The theme of this year’s competition is “This is Diabetes, This is Real,” aiming to capture the challenges, successes and day-to-day realities of people living with diabetes. “For our 2023...
In brief: Medline’s new leadership, AAH’s lobby day, women’s sleep quality
June 30, 2023HME News Staff
NORTHFIELD, Ill. – Medline CEO Charlie Mills, President Andy Mills and COO Jim Abrams plan to retire from their current roles after more than 26 years of leadership.
They will continue to serve on the company’s board of directors, with Charlie Mills leading as chairman and Andy Mills and Jim Abrams as vice chairmen.
Medline has promoted Jim Boyle to serve as its next CEO, and Jim Pigott as president & COO, effective Oct. 1, culminating a five-year succession planning...
Senseonics’ Eversense E3 offers accurate 365-day performance
June 28, 2023HME News Staff
GERMANTOWN, Md. – Senseonics Holdings highlighted new clinical data demonstrating the safety and accuracy of its Eversense E3 CGM system during a presentation at the American Diabetes Association 83rd Scientific Session. “These data further bolster Eversense’s position as a leading CGM choice for people with diabetes,” said Francine Kaufman, M.D., Senseonics chief medical officer. “These recent studies are an important step forward as we continue to expand awareness...
Senseonics secures coverage from UnitedHealthcare
June 5, 2023HME News Staff
GERMANTOWN, Md. – Senseonics Holdings has announced that UnitedHealthcare will begin providing coverage for the Eversense E3 CGM System effective July 1, 2023, for people with Type 1 and insulin-requiring Type 2 diabetes. "The policy update from UnitedHealthcare marks an important milestone for increased access to long-term CGM for people with diabetes,” said Tim Goodnow, PhD, president and CEO for Senseonics. “With the addition of UnitedHealthcare, we are nearing all insured adults...
In brief: Viemed acquisition, Philips recall, Quipt public offering
April 21, 2023HME News Staff
LAFAYETTE, La., - Viemed Healthcare will acquire Tennessee based Home Medical Products, a large regional provider of respiratory focused home medical solutions.
“We are incredibly excited to complement our strong history of organic growth by combining great teams through accretive transactions” said Casey Hoyt, Viemed CEO. “The purchase of HMP will launch our acquisition growth initiatives with a stellar organization that has an extraordinary reputation with patients, payors...
Eversense trial expands to pediatric diabetes patients
April 19, 2023HME News Staff
GERMANTOWN, Md. – The first pediatric patient in the ENHANCE clinical trial has been inserted with the Eversense 365-day system, said Senseonics Holdings, a medical technology company focused on the development of long-term implantable CGMs. “It’s a priority for Senseonics to extend the benefits of Eversense to the pediatric patient population,” said Francine Kaufman, MD, chief medical officer for Senseonics. “The differentiated features of our long-term implantable...
Ascensia completes initial launch of Eversense E3 in Europe
October 12, 2022HME News Staff
BASEL, Switzerland – Ascensia Diabetes Care has successfully completed the initial European launch of the next-generation Eversense E3 CGM System. The benefits of this fully-implantable, long-term CGM system are now available to people with diabetes in all launch markets across Europe in Germany, Switzerland, Poland, Italy, Spain, Norway, Sweden, the Netherlands and Andorra. “We are proud to have successfully brought the Eversense E3 to Europe, where we believe it can make a big difference...
Ascensia advances diabetes care – with purpose
June 17, 2022Theresa Flaherty, Managing Editor
PARSIPPANY, N.J. – Diabetes management is taking a “big leap forward” with the Eversense E3, an implantable continuous glucose monitor, which was recently approved for use up to six months, says Elaine Anderson, head of the Eversense CGM business unit at Ascensia Diabetes Care.
“This is double the lifetime of what people had – you replace it twice (a year),” she said. “It’s not sacrificing accuracy, it’s easy on, easy off so you can take...